Nov 16 (Reuters) -
* FDA - APPROVED STELFONTA TO TREAT DOGS WITH NON-METASTATIC, SKIN-BASED (CUTANEOUS) MAST CELL TUMORS
* FDA - ALSO APPROVING STELFONTA TO TREAT NON-METASTATIC MCTS LOCATED UNDER DOG'S SKIN (SUBCUTANEOUS), IN PARTICULAR AREAS OF DOG'S LEG
* FDA - GRANTED APPROVAL OF STELFONTA TO QBIOTICS GROUP LTD